Selumetinib has also been shown to inhibit secretion of cytokines such as IL-6 (Tai et al, 2007), IL-1β and tumour necrosis factor-α, which are implicated in the promotion of cancer cachexia (Zhang et al, 2007, 2008). Here, IL1B is linked to cancer.